Meeting
2022 ASCO Annual Meeting
Which angiosarcoma subtypes may benefit from immunotherapy?
Authors
Stefan G van Ravensteijn
Department of Medical Oncology Radboud University Medical Centre, Nijmegen, Netherlands
Stefan G van Ravensteijn , Yvonne MH Versleijen-Jonkers , Melissa HS Hillebrandt-Roeffen , Marije E Weidema , Maikel JL Nederkoorn , Mark AJ Gorris , Kiek Verrijp , Leonie I. Kroeze , Tessa de Bitter , Richarda M de Voer , Uta E Flucke , Ingrid Desar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11572)
DOI
10.1200/JCO.2022.40.16_suppl.11572
Abstract #
11572
Poster Bd #
476
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
First Author: Fuxue Huang
Poster
2022 ASCO Annual Meeting
Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.
First Author: Gennady Bratslavsky
Poster
2020 ASCO Virtual Scientific Program
Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.
First Author: Ethan Sokol